About Evolus Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.evolus.com/
Frequently Asked Questions
What is the 52-week range for EOLS?
The 52-week high is $9.31 and the 52-week low is $3.86.
What is the P/E ratio for EOLS?
The P/E ratio data is currently unavailable.
What is the dividend yield for EOLS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -410.18%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -10.85%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 126.60.
Analyst Recommendation Trends
Wall Street analyst consensus for EOLS over the last few months:
Latest EOLS News
FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action
The FDA objected to claims suggesting Jeuveau could make frown lines gone, deliver complete results, and begin working within two days.
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug
The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.
FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As Misleading
https://www.fda.gov/media/195157/download
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
NEWPORT BEACH, Calif., October 01, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support organizations and causes that positively impact their communities.
Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum Screen
Evolus (EOLS) passes Minervini Trend Template and high-growth momentum screen, showing technical strength, EPS acceleration and a breakout watch.
Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future
On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21% over the prior year, and the company followed that up by raising its full-year 2026 outlook. The quarter also marked the third straight period of […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | -105,108 | $9.0385 | $950,019 |
| 2026-03-20 | MOATAZEDI DAVID | -13,669 | $4.7501 | $64,929 |
| 2026-03-20 | Avelar Rui | -3,119 | $4.75 | $14,815 |
| 2026-03-17 | MOATAZEDI DAVID | -116,720 | $4.8883 | $570,562 |
| 2026-03-17 | Avelar Rui | -29,996 | $4.8883 | $146,629 |
| 2026-03-16 | MOATAZEDI DAVID | -67,489 | - | - |
| 2026-03-16 | MOATAZEDI DAVID | +67,489 | - | - |
| 2026-03-16 | Avelar Rui | -8,804 | - | - |
| 2026-03-16 | Avelar Rui | +8,804 | - | - |
| 2026-02-17 | Parschauer Karah Herdman | +45,559 | - | - |
| 2026-02-17 | Stewart Brady | +45,559 | - | - |
| 2026-02-17 | Mitchell Tatjana | +177,471 | - | - |
| 2026-02-17 | Mitchell Tatjana | +121,489 | - | - |
| 2026-02-17 | Mitchell Tatjana | +121,489 | - | - |
| 2026-02-17 | MOATAZEDI DAVID | +457,541 | - | - |
| 2026-02-17 | MOATAZEDI DAVID | +626,424 | - | - |
| 2026-02-17 | MOATAZEDI DAVID | +313,212 | - | - |
| 2026-02-17 | Malik Vikram | +45,559 | - | - |
| 2026-02-17 | Avelar Rui | +138,649 | - | - |
| 2026-02-17 | Avelar Rui | +94,913 | - | - |
| 2026-02-17 | Avelar Rui | +94,913 | - | - |
| 2026-02-17 | White Albert G III | +45,559 | - | - |
| 2026-02-17 | GILL DAVID N | +45,559 | - | - |
| 2025-12-22 | MOATAZEDI DAVID | -10,539 | $7.1507 | $75,361 |
| 2025-12-22 | Avelar Rui | -2,261 | $7.1507 | $16,168 |